세계의 비알코올성 지방간염 바이오마커 시장 보고서(2023년)

“Non-Alcoholic Steatohepatitis Biomarkers Global Market Report 2023 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on non-alcoholic steatohepatitis biomarkers market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for non-alcoholic steatohepatitis biomarkers ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The non-alcoholic steatohepatitis biomarkers market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of COVID-19 on supply chains and consumption patterns.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

• 1) By Type: Hepatic Fibrosis Biomarkers; Serum Biomarkers; Oxidative Stress Biomarkers; Apoptosis Biomarkers; Other Types

• 2) By Disease: Hypertension; Heart Disease; High Blood Lipid; Type 2 Diabetes; Obesity

• 3) By End Use: Research Institutes And Academics; Diagnostic Centres; Pharmaceutical Companies And Pharmaceutical Companies And Contract Research Organizations (CROs); Hospitals And Clinics; Other End-Uses

• Companies Mentioned: Genfit; Prometheus Laboratories Inc.; Siemens Medical Solutions USA Inc.; BioPredictive; Quest Diagnostics

• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA

• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

• Time series: Five years historic and ten years forecast.

• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,

• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.

• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

• Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Major players in the non-alcoholic steatohepatitis biomarkers market are Genfit, Prometheus Laboratories Inc., Siemens Medical Solutions USA Inc., BioPredictive, Quest Diagnostics, AstraZeneca Plc., Laboratory Corporation of America Holdings, Pfizer Inc., Bristol-Myers Squibb Company, NGM Biopharmaceuticals Inc., Gilead Sciences Inc., Perspectum Diagnostics Ltd., One Way Liver SL, Enterome SA, Echosens SA, Cisbio Bioassays SAS, Celerion Inc., Xeptagen SpA, Boehringer Ingelheim GmbH Inc., Exalenz Bioscience Ltd., Novartis AG, Novo Nordisk A/S, and Allergan PLC.

The global non-alcoholic steatohepatitis biomarkers market is expected to grow from $0.88 billion in 2022 to $1.10 billion in 2023 at a compound annual growth rate (CAGR) of 24.7%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The non-alcoholic steatohepatitis biomarkers market is expected to grow to $2.54 billion in 2027 at a CAGR of 23.2%.

The non-alcoholic steatohepatitis biomarkers market consists of sales of biomarkers such as apolipoprotein A1, apolipoprotein B, leptin and adiponectin. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Non-alcoholic steatohepatitis (NASH) is a type of liver inflammation and damage caused by a build-up of fat in the liver. NASH biomarkers are used as diagnostic tools to assess the severity of non-alcoholic steatohepatitis and to assess liver damage. This damages the liver cells and inflames the liver, which can result in cirrhosis (liver scarring) and liver failure. Biomarkers refer to a particular quality that can be tested to reveal pathogenic processes, healthy biological processes, or reactions to exposure or treatment.

North America was the largest region in the non-alcoholic steatohepatitis biomarkers market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the non-alcoholic steatohepatitis biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The main types of non-alcoholic steatohepatitis biomarkers include hepatic fibrosis biomarkers, serum biomarkers, oxidative stress biomarkers, apoptosis biomarkers and others. Hepatic fibrosis biomarkers refer to biomarkers for hepatic fibrosis, an overly exuberant wound healing in which excessive connective tissue develops in the liver. They are used to treat different diseases including hypertension, heart disease, high blood lipid, type 2 diabetes and obesity for use by various end-uses such as research institutes and academics, diagnostic centres, pharmaceutical companies and contract research organizations (CROs), hospitals and clinics and others..

The growing prevalence of non-alcoholic steatohepatitis (NASH) is expected to boost the growth of the non-alcoholic steatohepatitis biomarkers market going forward. Non-alcoholic steatohepatitis (NASH) is a severe case of fatty liver disease that is characterized by severe liver inflammation. The prevalence of NASH diseases is increasing due to the increasing number of overweight and obese patients. The non-alcoholic steatohepatitis biomarkers are used to diagnose and help better treat patients with NASH. For instance, in September 2020, according to "The Impact of Nonalcoholic Fatty Liver Disease in Primary Care: A Population Health Perspective," an article published by The American Journal of Medicine, a US-based peer-reviewed medical journal and the official journal of the Alliance for Academic Internal Medicine, the number of Americans who have non-alcoholic fatty liver disease will rise from 83.1 million in 2015 to 100.9 million in 2030. By 2030, It is anticipated that the incidence of non-alcoholic steatohepatitis (NASH), decompensated cirrhosis, and hepatocellular carcinoma will rise by 63%, 168%, and 137%, respectively. Non-alcoholic steatohepatitis (NASH) can progress from non-alcoholic fatty liver disease (NAFLD). Therefore, the growing prevalence of non-alcoholic steatohepatitis (NASH) is driving the growth of the non-alcoholic steatohepatitis biomarkers market.

Technological advancements are a key trend in gaining popularity in the non-alcoholic steatohepatitis biomarkers market. Major companies operating in the non-alcoholic steatohepatitis biomarkers market are focused on developing innovative solutions to strengthen their position in the market. For instance, in October 2022, GENFIT, a France-based late-stage biopharmaceutical company, and LabCorp, a US-based life sciences company, agreed on a five-year exclusive licensing deal for GENFIT's NIS4 technology to aid in identifying patients with non-alcoholic-steatohepatitis-at-risk (NASH). NIS4 technology is an innovative, multi-biomarker-based algorithm specifically developed to identify patients with non-alcoholic steatohepatitis (NASH) and significant to advanced fibrosis (F > 2), also referred to as at-risk NASH. As part of the agreement, LabCorp will develop and commercialize a blood-based molecular diagnostic test utilizing NIS4 technology in the United States and Canada, giving widespread access to healthcare professionals.

In June 2022, Novo Nordisk A/S, a Denmark-based pharmaceutical company partnered with Echosens SA. With this partnership, the companies intend to promote non-alcoholic steatohepatitis (NASH) early diagnosis and raise disease awareness among patients, medical professionals, and other stakeholders. Echosens SA is a France-based manufacturer of therapeutic monitoring and diagnostic devices.

The countries covered in the non-alcoholic steatohepatitis biomarkers market report are: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The non-alcoholic steatohepatitis biomarkers market research report is one of a series of new reports from The Business Research Company that provides non-alcoholic steatohepatitis biomarkers market statistics, including non-alcoholic steatohepatitis biomarkers industry global market size, regional shares, competitors with a non-alcoholic steatohepatitis biomarkers market share, detailed non-alcoholic steatohepatitis biomarkers market segments, market trends and opportunities, and any further data you may need to thrive in the non-alcoholic steatohepatitis biomarkers industry. This non-alcoholic steatohepatitis biomarkers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Table of Contents

1. Executive Summary

2. Non-Alcoholic Steatohepatitis Biomarkers Market Characteristics

3. Non-Alcoholic Steatohepatitis Biomarkers Market Trends And Strategies

4. Non-Alcoholic Steatohepatitis Biomarkers Market - Macro Economic Scenario

• 4.1. COVID-19 Impact On Non-Alcoholic Steatohepatitis Biomarkers Market
• 4.2. Ukraine-Russia War Impact On Non-Alcoholic Steatohepatitis Biomarkers Market
• 4.3. Impact Of High Inflation On Non-Alcoholic Steatohepatitis Biomarkers Market

5. Non-Alcoholic Steatohepatitis Biomarkers Market Size And Growth

• 5.1. Global Non-Alcoholic Steatohepatitis Biomarkers Historic Market, 2017-2022, $ Billion
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints On The Market
• 5.2. Global Non-Alcoholic Steatohepatitis Biomarkers Forecast Market, 2022-2027F, 2032F, $ Billion
  • 5.2.1. Drivers Of The Market
  • 5.2.2. Restraints On the Market

6. Non-Alcoholic Steatohepatitis Biomarkers Market Segmentation

• 6.1. Global Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• Hepatic Fibrosis Biomarkers
• Serum Biomarkers
• Oxidative Stress Biomarkers
• Apoptosis Biomarkers
• Other Types
• 6.2. Global Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• Hypertension
• Heart Disease
• High Blood Lipid
• Type 2 Diabetes
• Obesity
• 6.3. Global Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• Research Institutes And Academics
• Diagnostic Centres
• Pharmaceutical Companies And Contract Research Organizations (CROs)
• Hospitals And Clinics
• Other End-Uses

7. Non-Alcoholic Steatohepatitis Biomarkers Market Regional And Country Analysis

• 7.1. Global Non-Alcoholic Steatohepatitis Biomarkers Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 7.2. Global Non-Alcoholic Steatohepatitis Biomarkers Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

8. Asia-Pacific Non-Alcoholic Steatohepatitis Biomarkers Market

• 8.1. Asia-Pacific Non-Alcoholic Steatohepatitis Biomarkers Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 8.3. Asia-Pacific Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

9. China Non-Alcoholic Steatohepatitis Biomarkers Market

• 9.1. China Non-Alcoholic Steatohepatitis Biomarkers Market Overview
• 9.2. China Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F,$ Billion
• 9.3. China Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2017-2022, 2022-2027F, 2032F,$ Billion

10. India Non-Alcoholic Steatohepatitis Biomarkers Market

• 10.1. India Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 10.2. India Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

11. Japan Non-Alcoholic Steatohepatitis Biomarkers Market

• 11.1. Japan Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 11.2. Japan Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

12. Australia Non-Alcoholic Steatohepatitis Biomarkers Market

• 12.1. Australia Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 12.2. Australia Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

13. Indonesia Non-Alcoholic Steatohepatitis Biomarkers Market

• 13.1. Indonesia Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 13.2. Indonesia Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

14. South Korea Non-Alcoholic Steatohepatitis Biomarkers Market

• 14.1. South Korea Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 14.2. South Korea Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

15. Western Europe Non-Alcoholic Steatohepatitis Biomarkers Market

• 15.1. Western Europe Non-Alcoholic Steatohepatitis Biomarkers Market Overview
• 15.2. Western Europe Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 15.3. Western Europe Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

16. UK Non-Alcoholic Steatohepatitis Biomarkers Market

• 16.1. UK Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 16.2. UK Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

17. Germany Non-Alcoholic Steatohepatitis Biomarkers Market

• 17.1. Germany Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 17.2. Germany Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

18. France Non-Alcoholic Steatohepatitis Biomarkers Market

• 18.1. France Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 18.2. France Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

19. Eastern Europe Non-Alcoholic Steatohepatitis Biomarkers Market

• 19.1. Eastern Europe Non-Alcoholic Steatohepatitis Biomarkers Market Overview
• 19.2. Eastern Europe Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 19.3. Eastern Europe Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

20. Russia Non-Alcoholic Steatohepatitis Biomarkers Market

• 20.1. Russia Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 20.2. Russia Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

21. North America Non-Alcoholic Steatohepatitis Biomarkers Market

• 21.1. North America Non-Alcoholic Steatohepatitis Biomarkers Market Overview
• 21.2. North America Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 21.3. North America Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

22. USA Non-Alcoholic Steatohepatitis Biomarkers Market

• 22.1. USA Non-Alcoholic Steatohepatitis Biomarkers Market Overview
• 22.2. USA Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 22.3. USA Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

23. South America Non-Alcoholic Steatohepatitis Biomarkers Market

• 23.1. South America Non-Alcoholic Steatohepatitis Biomarkers Market Overview
• 23.2. South America Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 23.3. South America Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

24. Brazil Non-Alcoholic Steatohepatitis Biomarkers Market

• 24.1. Brazil Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 24.2. Brazil Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

25. Middle East Non-Alcoholic Steatohepatitis Biomarkers Market

• 25.1. Middle East Non-Alcoholic Steatohepatitis Biomarkers Market Overview
• 25.2. Middle East Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 25.3. Middle East Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

26. Africa Non-Alcoholic Steatohepatitis Biomarkers Market

• 26.1. Africa Non-Alcoholic Steatohepatitis Biomarkers Market Overview
• 26.2. Africa Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 26.3. Africa Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

27. Non-Alcoholic Steatohepatitis Biomarkers Market Competitive Landscape And Company Profiles

• 27.1. Non-Alcoholic Steatohepatitis Biomarkers Market Competitive Landscape
• 27.2. Non-Alcoholic Steatohepatitis Biomarkers Market Company Profiles
  • 27.2.1. Genfit
    • 27.2.1.1. Overview
    • 27.2.1.2. Products and Services
    • 27.2.1.3. Strategy
    • 27.2.1.4. Financial Performance
  • 27.2.2. Prometheus Laboratories Inc.
    • 27.2.2.1. Overview
    • 27.2.2.2. Products and Services
    • 27.2.2.3. Strategy
    • 27.2.2.4. Financial Performance
  • 27.2.3. Siemens Medical Solutions USA Inc.
    • 27.2.3.1. Overview
    • 27.2.3.2. Products and Services
    • 27.2.3.3. Strategy
    • 27.2.3.4. Financial Performance
  • 27.2.4. BioPredictive
    • 27.2.4.1. Overview
    • 27.2.4.2. Products and Services
    • 27.2.4.3. Strategy
    • 27.2.4.4. Financial Performance
  • 27.2.5. Quest Diagnostics
    • 27.2.5.1. Overview
    • 27.2.5.2. Products and Services
    • 27.2.5.3. Strategy
    • 27.2.5.4. Financial Performance

28. Key Mergers And Acquisitions In The Non-Alcoholic Steatohepatitis Biomarkers Market

29. Non-Alcoholic Steatohepatitis Biomarkers Market Future Outlook and Potential Analysis

30. Appendix

• 30.1. Abbreviations
• 30.2. Currencies
• 30.3. Historic And Forecast Inflation Rates
• 30.4. Research Inquiries
• 30.5. The Business Research Company
• 30.6. Copyright And Disclaimer